Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma

NCT03535870 is registered in ClinicalTrials.gov with West-Ward Pharmaceutical as lead sponsor.

NCT NCT03535870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03535870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Lead sponsor
West-Ward Pharmaceutical
Phase
Not applicable
Overall status
Completed
Start date
April 26, 2018
Completion date
September 10, 2019
Enrollment
1,556 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma